HUA HONG GRACE (01347.HK) fell 4.92% to HKD 89.900. GLOBALFOUNDRIES unveiled an FD-SOI platform for physical AI; TrendForce sees mature-node prices up in 2027.
EXCELLAND ROBOT (03231.HK) fell 0.34% to HKD 34.960. China issued a document on new quality productive forces; Shanghai targets 8,000 humanoid robots by 2028.
On 12 October 2026, LEADS BIOLABS-B (09887.HK) said vilasumu, a PD-L1/4-1BB bispecific antibody, received FDA Fast Track designation for first-line advanced biliary tract cancer, granted in nine days.
On 11 October 2026, EDDING GENOR (06998.HK) said the Phase II IND for GB268, a PD-1/CTLA-4/VEGF trispecific antibody, with chemotherapy for first-line locally advanced or metastatic colorectal adenocarcinoma was approved by China's NMPA on 9 October.
On 9 Oct 2026, CIRC (01763.HK) said its subsidiary obtained NMPA drug registration for a 50mg 13C-urea breath test kit; launch expected in December 2026.
On October 9, 2026, Hong Kong stocks rebounded, with the HSTECH up 3.06%. XIAOMI-W led AI concept stocks with a 9.72% gain, while ILUVATAR COREX fell 4.28%.
On October 9, 2026, BIDU-W (09888.HK) trended upward. As of 13:59, it traded at HK$83.25, up 1.34%.
ASMPT (00522.HK) fell 3.79% to HKD 157.600. GlobalFoundries signed a USD 2bn silicon interposer deal with TSMC for CoWoS; TSMC September revenue rose 54.6%.
XIAOMI-W (01810.HK) rose 7.44% to HKD 25.420. China has 70-plus embodied intelligence training grounds in use; EWPT shipped over 1.1 million robot parts.
On 9 October 2026, VIRTUAL MIND (01520.HK) said it signed a strategic cooperation letter of intent with Australia's OZBeat AI Group PTY LTD covering AIGC, AI content identity and digital copyright infrastructure, AI digital employee systems and the creator commercialization ecosystem, with formal agreements still to be negotiated.
On 8 Oct 2026, SUNSHINE PHARMA (06887.HK) won NMPA approval for its insulin degludec/aspart injection, taking its approved insulin range in China to 7.
On 8 Oct 2026, CSPC PHARMA (01093.HK) unveiled Phase I data for SYS6002 in cervical cancer at IGCS 2026: confirmed ORR 35.9% and 28.6%; Phase III started.
On 8 Oct 2026, SILKWAVE INC (00471.HK) signed an MOU with Thailand's Altura UAV on industrial drone R&D, manufacturing and market expansion; it is non-binding.
On 8 October 2026, SSY GROUP (02005.HK) said it won NMPA production approval for nimodipine oral solution (10ml:60mg) in China, a Category 3 chemical drug.
On October 8, 2026, Hong Kong stocks fell broadly, with the HSTECH down 2.89% to a new low since September 2024. MINIMAX-W slumped 13.74%; BABA-W eased 1.04%.
On 8 October 2026, SBP GROUP (01177.HK) said the Phase III PACER-III trial of its TQC3721 inhalation suspension for COPD in China completed full enrolment.
